Urine lipoarabinomannan to monitor antituberculosis therapy response and predict mortality in an HIV-endemic region:A prospective cohort study

PK Drain; L Gounder; A Grobler; F Sahid; IV Bassett; MYS Moosa

Journal article

Urine lipoarabinomannan to monitor antituberculosis therapy response and predict mortality in an HIV-endemic region:A prospective cohort study

PK Drain, L Gounder, A Grobler, F Sahid, IV Bassett, MYS Moosa

BMJ Open | BMJ PUBLISHING GROUP | Published : 2015

DOI: 10.1136/bmjopen-2014-006833

Open access

Download PDF

Abstract

Objective: To determine if urinary lipoarabinomannan (LAM) may serve as a biomarker to monitor antituberculosis (TB) therapy response, and whether LAM results before and after treatment are predictive of patient outcomes. Design: Prospective cohort. Setting: Outpatient referral clinic and tertiary hospital in South Africa. Participants: Adults (≥18 years) with ≥2 TB-related symptoms (cough, fever, weight loss, night sweats) for ≥2 weeks being initiated on anti-TB therapy. Interventions: On enrolment, we obtained urine and nebulised sputum specimens, offered HIV testing and started participants on anti-TB therapy for ≥6 months. We collected urine samples after the 2-month intensive treatment ..

View full abstract

University of Melbourne Researchers

Anneke Grobler Author

Grants

Awarded by National Institute of Allergy and Infectious Diseases

Funding Acknowledgements

This study was funded by the Medical Research Council of South Africa, the Howard Hughes Medical Institute, the KwaZulu-Natal Research Institute for TB and HIV (K-RITH), and the UK's Department for International Development. Dr Drain was supported by the Harvard Global Health Institute, the Fogarty International Clinical Research Scholars and Fellows Program at Vanderbilt University (R24 TW007988), the Infectious Disease Society of America Education & Research Foundation (IDSA ERF) and National Foundation for Infectious Diseases (NFID), The Program in AIDS Clinical Research Training Grant (T32 AI007433), the National Institute of Allergy and Infectious Disease (K23 AI108293), the Harvard University Center for AIDS Research (P30 AI060354) and the Massachusetts General Hospital Executive Committee on Research. Dr Bassett was supported by the National Institute of Mental Health R01 MH090326 (IVB) and the Claflin Distinguished Scholar Award (IVB).